Denali Therapeutics Inc. Finance Lease, Right-of-Use Asset, after Accumulated Amortization
Denali Therapeutics Inc. (DNLI) had Finance Lease, Right-of-Use Asset, after Accumulated Amortization of $46.70 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:FinanceLeaseRightOfUseAsset · last filed 2026-08-06
- 2026-06-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $46.70M.
- 2026-03-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $47.62M.
- 2025-12-31: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $48.53M.
- 2025-09-30: Finance Lease, Right-of-Use Asset, after Accumulated Amortization $49.45M.
| Period end | Finance Lease, Right-of-Use Asset, after Accumulated Amortization |
|---|---|
| 2026-06-30 | $46.70M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $47.62M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $48.53M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $49.45M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $50.36M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $50.20M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $47.53M 10-K · filed 2026-02-26 |
| 2024-09-30 | $38.69M 10-Q · filed 2024-11-06 |
| 2023-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |